Biofil Chemicals and Pharmaceuticals Limited (BOM:524396)

BOM:524396 Financials Overview

Financials in millions INR. Fiscal year is April - March.

Revenue & Profits

Chart

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Revenue Revenue Growth	346.26	314.78	335.82	404.09	300.35	223.82
Revenue Growth	1.26%	-6.27%	-16.89%	34.54%	34.19%	-37.50%
Gross Profit Gross Profit Growth	24.83	51.91	25.67	27.48	25.63	28.66
Operating Income Operating Income Growth	8.23	34.6	7.29	9	8.34	10.34
Net Income Net Income Growth	4.84	27.86	5.58	7.09	5.6	6.98
Earnings Per Share EPS Growth	0.30	1.71	0.34	0.44	0.34	0.43
EPS Growth	-82.57%	402.94%	-21.98%	28.17%	-20.77%	-43.74%

Revenue by Segment

Chart

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024
Period Ending	Jun 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024
Pharma Division Pharma Division Growth	172.5	189.63	266.6	278.68
Chemical Division Chemical Division Growth	170.63	94.32	67.42	121.67
Total Total Growth	343.13	283.95	334.02	400.35

Cash & Debt

Chart

Fiscal Year	Current	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Cash & Investments Cash & Investments Growth	33.26	33.26	2.55	22.84	0.38	1.45
Total Debt Total Debt Growth	30.2	30.2	4.71	4.39	5.22	4.65
Net Cash (Debt) Net Cash Growth	3.06	3.06	-2.16	18.45	-4.85	-3.2
Net Cash Growth	-	-	-	-	-	-
Net Cash Per Share Net Cash Per Share Growth	0.19	0.19	-0.13	1.13	-0.30	-0.20

Cash Flow & CapEx

Chart

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Operating Cash Flow Operating Cash Flow Growth	-	-6.05	-19.24	23.94	-1.12	-2.2
Capital Expenditures CapEx Growth	-	-2.01	-1	-0.23	-0.11	-0.7
Free Cash Flow Free Cash Flow Growth	-	-8.05	-20.24	23.71	-1.22	-2.9
Free Cash Flow Growth	-	-	-	-	-	-

Margins

Chart

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Gross Margin	7.17%	16.49%	7.64%	6.80%	8.53%	12.80%
Operating Margin	2.38%	10.99%	2.17%	2.23%	2.78%	4.62%
Pretax Margin	2.37%	10.96%	2.19%	2.14%	2.64%	4.53%
Profit Margin	1.40%	8.85%	1.66%	1.75%	1.87%	3.12%
FCF Margin	-	-2.56%	-6.03%	5.87%	-0.41%	-1.29%

Valuation

Chart

Fiscal Year	Current	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Aug 18, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
PE Ratio	104.97	15.12	120.02	138.51	120.34	134.68
P/FCF Ratio	-	-	-	41.43	-	-
PS Ratio	1.48	1.34	1.99	2.43	2.25	4.20

Data Source: S&P Global Market Intelligence Last updated: Jun 30, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Aug 17, 2026

Data Sources Report a data error